Home >  Registry
     
 
 Protocol Registry Trial Results IFPMA Background Links
About this Registry

This registry serves as a global repository for information on ongoing Roche Pharmaceuticals Phase II to Phase IV clinical studies, Phase I studies in patients and Roche Diagnostics interventional studies on advanced diagnostic products.

For More Information 

Common Questions
More Frequently Asked Questions 
Overview of Clinical Trials 
Glossary of Terms 
Phase Definitions 
Field Definitions 
Roche Clinical Trial Global Policy 
Site Provided by Thomson CenterWatch

Lymphocytic Leukemia, Chronic

  • A Study of Maintenance Treatment With MabThera (Rituximab) in Patients With Progressive B-cell Chronic Lymphocytic Leukemia
    Not yet recruiting


  • A Study of MabThera (Rituximab) Plus Chlorambucil in Patients With Chronic Lymphocytic Leukemia.
    Recruiting


  • A Study of MabThera (Rituximab) in First Line Treatment of Chronic Lymphocytic Leukemia.
    Recruiting


  • A Study of MabThera (Rituximab) in Patients With Chronic Lymphocytic Leukemia (CLL)
    Recruiting


  • A Study to Evaluate MabThera (Rituximab) in Patients Previously Treated for Chronic Lymphocytic Leukemia
    No longer recruiting


  • A Study of MabThera (Rituximab) in Combination With a Chemotherapy Regimen for the Treatment of Chronic Lymphocytic Leukemia.
    No longer recruiting


  • CHAIROS study A Study of MabThera (Rituximab) Maintenance Therapy in Patients With B-Cell Chronic Lymphocytic Leukemia (CLL) Naive to Chemotherapy
    No longer recruiting


  • A Study of MabThera (Rituximab) in Patients With Chronic Lymphocytic Leukemia (CLL) Responsive to First Line Therapy
    Completed


  • A Study of MabThera (Rituximab) in Combination Chemotherapy in Patients With B-Cell Chronic Lymphocytic Leukemia
    Completed


    		•

    © 1996-2008 F.Hoffmann-La Roche Ltd See our legal Statement